PRIMARY SCLEROSING CHOLANGITIS
Clinical trials for PRIMARY SCLEROSING CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY SCLEROSING CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare liver disease: drug trial targets bile duct damage
Disease control OngoingThis study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also look at blood tests to see if…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare liver disease: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests an experimental drug called CS0159 in 50 people with primary sclerosing cholangitis (PSC), a rare liver disease. The study has a 12-week placebo-controlled phase followed by a 40-week open-label period to check safety and how well the drug works. Research…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could ditching gluten ease two tough gut diseases?
Disease control OngoingThis study looks at whether a gluten-free diet can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in symptoms, gut bacteria, and lab results in 60 adults over time. The goal is to see if avoiding gluten c…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: NA • Sponsor: Institute for Clinical and Experimental Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a common cholesterol drug help fight a rare liver disease?
Disease control OngoingThis Phase 3 trial tests whether taking 40 mg of simvastatin daily for 5 years can improve outcomes for people with primary sclerosing cholangitis (PSC), a rare liver disease. About 560 patients will receive either simvastatin or a placebo. Researchers will track survival, need f…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE3 • Sponsor: Annika Bergquist • Aim: Disease control
Last updated Jun 26, 2026 13:35 UTC
-
New biomarkers may sharpen cancer diagnosis in bile duct blockages
Diagnosis OngoingThis study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Sponsor: AdventHealth • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New hope for PSC patients: drug targets debilitating itch
Symptom relief OngoingThis study tests a medicine called volixibat to see if it can reduce severe itching in people with primary sclerosing cholangitis (PSC), a rare liver disease. About 182 participants will receive either volixibat or a placebo, and researchers will track itch scores using a daily d…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC